Mode
Text Size
Log in / Sign up
Phase 2 N=70 Randomized Quadruple-blind Treatment

Safety and Efficacy of Nemolizumab in PN

Prurigo Nodularis

Enrolled (actual)
70
Serious AEs
10.0%
Results posted
Feb 2020
Primary outcome: Primary: Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) Score at Week 4 Using Last Observation Carried Forward (LOCF) Approach — -13.8; -52.6 Percent change

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
CD14152 Dose A (Drug); CD14152 placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Galderma R&D
Primary completion
Sep 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale (NRS) Score at Week 4 Using Last Observation Carried Forward (LOCF) Approach
-13.8; -52.6
PRIMARY
Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Week 4 Using Multiple Imputation (MI) Method
-18.3; -52.0
PRIMARY
Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Week 4 Using Observed Data
-15.2; -54.9
SECONDARY
Percent Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach
-6.1; -26.0; -7.4; -41.7; -13.8; -52.6
SECONDARY
Absolute Change From Baseline in Weekly Average of the Peak Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach
-0.5; -2.1; -0.6; -3.4; -1.2; -4.3
SECONDARY
Percent Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach
-7.5; -26.6; -9.6; -44.0; -16.5; -53.4
SECONDARY
Absolute Change From Baseline in Weekly Average of the Average Pruritus Numeric Rating Scale Score at Each Visit Using LOCF Approach
-0.5; -1.9; -0.8; -3.2; -1.3; -3.9
SECONDARY
Percent Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale (VRS) Score at Each Visit Using LOCF Approach
-9.8; -27.6; -12.3; -39.1; -15.6; -50.7
SECONDARY
Absolute Change From Baseline in Weekly Average of the Peak of Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach
-0.3; -0.9; -0.4; -1.3; -0.6; -1.6
SECONDARY
Percent Change From Baseline in Weekly Average of the Average Pruritus Verbal Rating Scale Score at Each Visit Using LOCF Approach
-10.5; -29.6; -13.0; -42.9; -16.4; -52.1
SECONDARY
Absolute Change From Baseline in Weekly Average of the Average Verbal Rating Scale Score at Each Visit Using LOCF Approach
-0.4; -0.9; -0.4; -1.3; -0.6; -1.6
SECONDARY
Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4)
4.3; 5.0; 4.0; 5.3; 4.0; 5.7
SECONDARY
Prurigo Activity Score (PAS) Item 5: Overall Number of Prurigo Lesions at Week 12
87.1; 84.9; 74.2; 54.8
SECONDARY
Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit
0; 0; 2; 4; 7; 5
SECONDARY
Investigator Global Assessment (IGA) Score at Each Visit
3.4; 3.5; 3.3; 2.8; 3.1; 2.4
SECONDARY
Percentage of Participants Achieving Investigator Global Assessment Success (Defined as IGA= 0 [Clear] or IGA = 1 [Almost Clear] With Two-point Improvement From Baseline) at Week 12
2.8; 20.6

Summary

The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.

Eligibility Criteria

Inclusion Criteria

  • Male or female of at least 18 years at screening
  • Clinical diagnosis of PN for at least 6 months with:
  • Prurigo lesions on upper limbs with or without lesions on the trunk or lower limbs
  • At least 20 nodules on the entire body with a bilateral distribution
  • Severe pruritus defined as follows on a Numerical Rating Scale (NRS)
  • At the Screening visit 1: Mean of the worst daily intensity of the NRS score is ≥ 7 over the previous 3 days
  • At the Baseline visit: Mean of the worst daily intensity of the NRS score is ≥ 7 over the previous week; NOTE: NRS score should be measured on at least 5 days during the week preceding the baseline visit.
  • Female subjects must fulfill one of the criteria below:
  • Female subjects of non-childbearing potential (postmenopausal [absence of menstrual bleeding for 1 year prior to screening, without any other medical reason], hysterectomy or bilateral oophorectomy);
  • Female subjects of childbearing potential who agree to a true abstinence (when in line with the preferred and usual lifestyle of the subject), or to use an effective method of contraception throughout the clinical trial and for 120 days after the last study drug administration:

Exclusion Criteria

  • Chronic pruritus resulting from another condition than PN such as scabies, insect bite, lichen simplex chronicus, psoriasis, acne, folliculitis, habitual picking, lymphomatoid papulosis, chronic actinic dermatitis, dermatitis herpetiformis, sporotrichosis, bullous disease
  • Unilateral lesions of prurigo (e.g only one arm affected)
  • Cutaneous bacterial or viral infection within 1 week before the baseline visit.
  • Infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 1 week before the screening visit, or during the screening period, unless completely resolved at the screening/ baseline visits respectively,
  • Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results and/or put the subject at Chronic pruritus resulting from another condition than PN such as scabies, insect bite, lichen simplex chronicus, psoriasis, acne, folliculitis, habitual picking, lymphomatoid papulosis, chronic actinic dermatitis, dermatitis herpetiformis, sporotrichosis, bullous disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03181503). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search